Blend identity and evidence limits
CJC-1295/Ipamorelin Blend
Evidence for the named components and why it does not validate a mixed growth-hormone product.
Source and review status
Identity unresolved
Identity search checked on: 6 September 2026
Qualified clinical review: Pending. This page has not been clinically reviewed.
About this source check
AI-assisted editorial source checking covers the cited material and its stated limits. It is not a systematic review, verification of a supplied product, or clinical sign-off.
Editorial role: InfoAddict. Last material change: 6 September 2026. Next source review: 6 December 2026.
Which CJC-1295 is meant
This blend name does not establish the CJC-1295 form or a verified ratio with ipamorelin. The early CJC-1295 research concerned a long-acting GHRH analogue. That study product should not be assumed to match a different preparation bearing a similar name.
Sources: Teichman and colleagues, Journal of Clinical Endocrinology & Metabolism; indexed by PubMed
What the human studies measured
Two short studies, lasting 28 and 49 days, measured growth hormone and IGF-I in healthy adults receiving CJC-1295 alone. Hormone changes were observed, but these are not evidence that an ipamorelin blend improves strength, injury recovery or longevity.
Sources: Teichman and colleagues, Journal of Clinical Endocrinology & Metabolism; indexed by PubMed
Component risks and unanswered questions
FDA describes increased heart rate and systemic vasodilation associated with CJC-1295. For ipamorelin, its assessment distinguishes an intravenous study with serious events from other routes with inadequate safety data. These component findings do not quantify the risk of this mixture.
Sources: U.S. Food and Drug Administration
A meaningful blend assessment would need the exact identities, formulation and combination-specific human evidence. The catalogue label supplies none of those assurances.
Published sources
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman and colleagues, Journal of Clinical Endocrinology & Metabolism; indexed by PubMed. Published March 2006; online 13 December 2005; accessed 6 September 2026.
Supports: Short studies of long-acting CJC-1295 alone and hormone measurements, not outcomes for an ipamorelin blend.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
U.S. Food and Drug Administration. Current FDA reference; accessed 6 September 2026.
Supports: Named substance and route-specific safety findings. Ingredient assessments do not validate a finished blend.
Change history
| Date | Change | Clinical-review status |
|---|---|---|
| 6 September 2026 | Identity and evidence limits documented | Pending |
Keep a private record
UpgradeYourself lets you keep private records of routines and observations you choose to discuss with a qualified health professional. This reference does not recommend starting, stopping or changing an item.